Finding New Ways to Fight Bacterial Infections
A single-cell approach to developing non-traditional antibiotics
This work aims to discover completely new types of antibiotics to overcome the growing problem of drug-resistant bacterial infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Princeton University NIH-funded |
| Lab location | 1 site (Princeton, UNITED STATES) |
| Project ID | NIH-11187073 on NIH RePORTER |
What this research studies
For many years, bacteria have become resistant to our current antibiotics, and very few new drugs have been developed to replace them. This project uses a groundbreaking technology called M3-Seq to look at how bacteria and human cells interact, one cell at a time. By understanding these interactions in great detail, researchers hope to uncover entirely new ways to stop infections. This innovative approach could lead to the next generation of medicines to protect us from dangerous bacteria.
Who could benefit from this research
Good fit: This foundational research is not recruiting patients directly but aims to benefit future patients suffering from bacterial infections, especially those caused by drug-resistant bacteria.
Not a fit: Patients without bacterial infections or those whose infections are treatable with current antibiotics may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to the development of powerful new antibiotics that can treat infections currently resistant to existing drugs, offering hope for patients with serious bacterial illnesses.
How similar studies have performed: This project uses novel single-cell sequencing methods, representing a new approach to antibiotic discovery, as traditional methods have yielded few new drugs recently.
Where this research is happening
Princeton, UNITED STATES
- Princeton University — Princeton, United States (Active)
Researchers
- Principal investigator: Gitai, Zemer — Princeton University
- Study coordinator: Gitai, Zemer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.